Bruker (NASDAQ:BRKR) Stock Crosses Below Fifty Day Moving Average – Time to Sell?

Bruker Corporation (NASDAQ:BRKR – Get Free Report)’s stock price crossed below its 50-day moving average during trading on Friday. The stock has a 50-day moving average of $59.99 and traded as low as $56.13. Bruker shares last traded at $56.46, with a volume of 2,250,882 shares.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the stock. Wall Street Zen downgraded shares of Bruker from a “buy” rating to a “hold” rating in a research note on Saturday. Guggenheim boosted their price target on Bruker from $70.00 to $72.00 and gave the stock a “buy” rating in a research report on Thursday, October 1st. Stifel Nicolaus set a $50.00 price objective on Bruker in a research note on Wednesday, August 5th. Royal Bank Of Canada started coverage on Bruker in a research report on Friday. They set a “sector perform” rating and a $66.00 target price for the company. Finally, Zacks Research downgraded Bruker from a “strong-buy” rating to a “hold” rating in a report on Wednesday, September 2nd. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $61.00.

Check Out Our Latest Stock Report on Bruker

Bruker Stock Down 9.1%

The stock has a market capitalization of $8.62 billion, a P/E ratio of -51.33, a P/E/G ratio of 1.64 and a beta of 1.26. The firm’s fifty day moving average is $59.99 and its 200-day moving average is $51.31. The company has a current ratio of 1.84, a quick ratio of 0.90 and a debt-to-equity ratio of 0.74.

Bruker (NASDAQ:BRKR – Get Free Report) last issued its quarterly earnings results on Wednesday, November 4th. The medical research company reported $0.56 EPS for the quarter, topping the consensus estimate of $0.42 by $0.14. The company had revenue of $874.00 million during the quarter, compared to analysts’ expectations of $865.16 million. Bruker had a negative net margin of 3.82% and a positive return on equity of 13.76%. Bruker’s revenue was up 1.6% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.45 EPS. As a group, equities research analysts predict that Bruker Corporation will post 2.13 earnings per share for the current year.

Bruker Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, January 7th. Shareholders of record on Monday, December 21st will be issued a dividend of $0.05 per share. The ex-dividend date is Monday, December 21st. This represents a $0.20 annualized dividend and a yield of 0.4%. Bruker’s payout ratio is currently -18.18%.

Insider Buying and Selling

In other Bruker news, VP Mark Munch sold 2,000 shares of Bruker stock in a transaction that occurred on Tuesday, September 15th. The shares were sold at an average price of $52.87, for a total value of $105,740.00. Following the transaction, the vice president owned 134,806 shares of the company’s stock, valued at approximately $7,127,193.22. The trade was a 1.46% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Company insiders own 27.20% of the company’s stock.

Institutional Investors Weigh In On Bruker

Several institutional investors have recently added to or reduced their stakes in the stock. American Century Companies Inc. raised its holdings in shares of Bruker by 64.1% in the third quarter. American Century Companies Inc. now owns 45,966 shares of the medical research company’s stock valued at $2,976,000 after purchasing an additional 17,957 shares during the last quarter. Kestra Advisory Services LLC boosted its holdings in Bruker by 6.0% during the third quarter. Kestra Advisory Services LLC now owns 4,947 shares of the medical research company’s stock worth $320,000 after purchasing an additional 282 shares during the last quarter. Coastal Bridge Advisors LLC acquired a new position in Bruker during the third quarter worth $254,000. Integrated Wealth Concepts LLC grew its position in Bruker by 14.9% in the third quarter. Integrated Wealth Concepts LLC now owns 8,491 shares of the medical research company’s stock valued at $550,000 after purchasing an additional 1,101 shares in the last quarter. Finally, Allworth Financial LP grew its position in Bruker by 40.3% in the third quarter. Allworth Financial LP now owns 5,434 shares of the medical research company’s stock valued at $352,000 after purchasing an additional 1,561 shares in the last quarter. 79.52% of the stock is owned by institutional investors.

About Bruker

(Get Free Report)

Bruker develops and manufactures scientific instruments and analytical technologies used to study biological, chemical and physical materials. Its products support research and testing in areas including life sciences, pharmaceuticals, biotechnology, materials science, chemicals and clinical diagnostics. The company’s offerings include nuclear magnetic resonance and electron paramagnetic resonance systems, mass spectrometers, X-ray and microscopy instruments, and infrared and Raman spectroscopy solutions.

Featured Articles

Receive News & Ratings for Bruker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker and related companies with MarketBeat.com's FREE daily email newsletter.